|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2006-2-22
|
|
pubmed:abstractText |
To investigate the immunoreactive trypsinogen (IRT) values above the usual 99th centile laboratory cut-off and determine the value of offering further testing to those infants with a markedly elevated IRT but no cystic fibrosis transmembrane regulator (CFTR) gene mutation identified by the screening programme.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1468-2044
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
91
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
222-5
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:16243854-Biological Markers,
pubmed-meshheading:16243854-Cystic Fibrosis,
pubmed-meshheading:16243854-Cystic Fibrosis Transmembrane Conductance Regulator,
pubmed-meshheading:16243854-DNA Mutational Analysis,
pubmed-meshheading:16243854-False Positive Reactions,
pubmed-meshheading:16243854-Female,
pubmed-meshheading:16243854-Genetic Testing,
pubmed-meshheading:16243854-Heterozygote,
pubmed-meshheading:16243854-Homozygote,
pubmed-meshheading:16243854-Humans,
pubmed-meshheading:16243854-Infant, Newborn,
pubmed-meshheading:16243854-Male,
pubmed-meshheading:16243854-Mutation,
pubmed-meshheading:16243854-Neonatal Screening,
pubmed-meshheading:16243854-Reference Values,
pubmed-meshheading:16243854-Trypsinogen
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testing.
|
|
pubmed:affiliation |
Department of Respiratory Medicine, Royal Children's Hospital, Parkville, Victoria, Australia. john.massie@rch.org.au
|
|
pubmed:publicationType |
Journal Article,
Evaluation Studies
|
